|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:Biogen
2020
$800 million
|
|
gptkbp:businessModel
|
partnerships
collaborative research
biopharmaceutical development
|
|
gptkbp:CEO
|
gptkb:David_P._Schaffer
|
|
gptkbp:clinicalTrials
|
gptkb:NSR-REP1
gptkb:NSR-RARE
biopharmaceutical company
NSR-ABC
Phase 1 trial for NSR-RARE
Phase 1 trial for NSR-REP1
Phase 1/2 trial for NSR-REP1
Phase 2 trial for NSR-RARE
Phase 2 trial for NSR-REP1
Phase 3 trial for NSR-RARE
Phase 3 trial for NSR-REP1
NSR-XYZ
|
|
gptkbp:collaborations
|
gptkb:Duke_University
gptkb:Harvard_University
gptkb:University_of_Pennsylvania
gptkb:Massachusetts_Eye_and_Ear
gptkb:Boston_Children's_Hospital
|
|
gptkbp:focus
|
gene therapy
|
|
gptkbp:founded
|
2013
|
|
gptkbp:founder
|
gptkb:David_P._Schaffer
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nightstar Therapeutics
|
|
gptkbp:investmentFocus
|
gptkb:New_Enterprise_Associates
gptkb:Sofinnova_Partners
gptkb:Morningside_Ventures
2018
OrbiMed Advisors
|
|
gptkbp:market
|
rare diseases
orphan drugs
|
|
gptkbp:partnerships
|
gptkb:University_of_California,_Berkeley
|
|
gptkbp:platforms
|
gene editing
gene delivery
|
|
gptkbp:products
|
gptkb:NSR-REP1
gptkb:NSR-RARE
|
|
gptkbp:regulatoryCompliance
|
FDA_approval
EMA_approval
|
|
gptkbp:research_areas
|
eye diseases
genetic disorders
|
|
gptkbp:research_focus
|
Leber congenital amaurosis
retinitis pigmentosa
|
|
gptkbp:specializesIn
|
retinal diseases
|
|
gptkbp:supportRole
|
experts in gene therapy
experts in ophthalmology
experts in biopharmaceuticals
experts in genetic disorders
|
|
gptkbp:targetMarket
|
ophthalmology
|
|
gptkbp:technology
|
AAV_vector_technology
|